tradingkey.logo

Aadi Bioscience Inc <AADI.OQ> expected to post a loss of 22 cents a share - Earnings Preview

ReutersMar 7, 2025 12:34 PM
  • Aadi Bioscience Inc AADI.OQ AADI.O is expected to show a rise in quarterly revenue when it reports results on March 11 (estimated) for the period ending December 31 2024

  • The Pacific Palisades California-based company is expected to report a 17.8% increase in revenue to $7.45 million from $6.33 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Aadi Bioscience Inc is for a loss of 22 cents per share.

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Aadi Bioscience Inc is $3.00​, above​ its last closing price of $2.10. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2024

-0.38

-0.46

-0.46

Met

-0.5

Jun. 30 2024

-0.69

-0.69

-0.54

Beat

21.7

Mar. 31 2024

-0.63

-0.64

-0.68

Missed

-5.8​

Dec. 31 2023

-0.65

-0.60

Beat

7.4

​​Sep. 30 2023

-0.72

-0.72

-0.60

Beat

17.1

Jun. 30 2023

-0.61

-0.62

-0.67

Missed

-7.7​

Mar. 31 2023

-0.58

-0.58

-0.57

Beat

2.4

Dec. 31 2022

-0.71

-0.52

Beat

26.8

This summary was machine generated March 7 at 12:34 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI